trudhesa
trudhesa: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| IPI Legacy Liquidation Co (IMPL) | Approved |
FDA Decisions
Frequently asked questions
Who is developing trudhesa?
trudhesa is being developed by IPI Legacy Liquidation Co.
What is trudhesa's latest FDA decision?
The most recent tracked FDA decision for trudhesa is Approval for 1 INDICATIONS AND USAGE TRUDHESA is indicated for the acute treatment of migraine with or without aura in adults. TRUDHESA is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use : TRUDHESA is not indicated for the preventive treatment of migraine or for the management of hemiplegic or basilar migraine. ( 1 ) Limitations of Use TRUDHESA is not indicated for the preventive treatment of migraine. TRUDHESA is not indicated f, dated September 2, 2021.
Get deeper analysis on trudhesa
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis